Tumor Biology

, Volume 37, Issue 7, pp 9411–9422 | Cite as

Gastric cardia adenocarcinoma microRNA profiling in Chinese patients

  • Shegan Gao
  • Fuyou Zhou
  • Chen Zhao
  • Zhikun Ma
  • Ruinuo Jia
  • Shuo Liang
  • Mengxi Zhang
  • Xiaojuan Zhu
  • Pengfei Zhang
  • Lu Wang
  • Feng Su
  • Jiangman Zhao
  • Gang Liu
  • Bo Peng
  • Xiaoshan Feng
Original Article

Abstract

Gastric cardia adenocarcinoma (GCA), which occurs at the gastroesophageal boundary, is one of the most malignant types of cancer. Over the past 30 years, the incidence of GCA has increased by approximately sevenfold, which has a more substantial increase than that of many other malignancies. However, as previous studies mainly focus on non-cardia gastric cancer, until now, the mechanisms behind GCA remain largely unknown. MicroRNAs (miRNAs) have been shown to play pivotal roles in carcinogenesis. To gain insight into the molecular mechanisms regulated by miRNAs in GCA development, we investigated miRNA expression profiles using 81 pairs of primary GCAs and corresponding non-tumorigenic tissues. First, 21 pairs of samples were used for microarray analysis, and then another 60 pairs of samples were used for further analysis. Our results showed that 464 miRNAs (237 upregulated, 227 downregulated, false discovery rate FDR <0.05) were differently expressed between GCA and non-tumor tissues. Pearson test and pathway analysis revealed that these dysregulated miRNA correlated coding RNAs may have effects on several cancer-related pathways. Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation. One miRNA, miR-196a-5p, was found to be associated with age of GCA onset. Further, survival analysis showed that the expression level of miR-135b-5p was associated with GCA survival. Taken together, our study first provided the genome-wide expression profiles of miRNA in GCA and will be good help for further functional studies.

Keywords

microRNA Microarray Gastric cardia adenocarcinoma Differentiation miR135b-5p 

Supplementary material

13277_2016_4824_MOESM1_ESM.doc (400 kb)
Table S1Significantly down- and up-regulated miRNAs. (DOC 400 kb)
13277_2016_4824_MOESM2_ESM.tif (125 kb)
Supplementary Fig S1Validation of EIF2 pathway and mTOR pathway. A, fold change of four important genes in EIF2 pathway (tumor/normal); B, fold change of four important genes in mTOR pathway (tumor/normal). (TIF 125 kb)
13277_2016_4824_MOESM3_ESM.tif (5.2 mb)
Supplementary Fig. S2Examples of well (A), medium (B), and poor (C)differentiation GCA samples (200×). (TIF 5291 kb)
13277_2016_4824_MOESM4_ESM.tif (5.8 mb)
ESM 1(TIF 5931 kb)

References

  1. 1.
    Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. Jama. 1991;265:1287–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Deans C, Yeo MS, Soe MY, Shabbir A, Ti TK, So JB. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35:617–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Okholm C, Svendsen LB, Achiam MP. Status and prognosis of lymph node metastasis in patients with cardia cancer—a systematic review. Surg Oncol. 2014;23:140–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010;28:5210–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gao SG, Wang LD, Feng XS, Ma BG, Wang QM, Guo RF, et al. Expression of p53 and PCNA in intestinal metaplasia tissue adjacent to gastric cardia adenocarcinoma and in gastric cardia biopsy tissue. J Zhengzhou University . 2006;1:30–2.Google Scholar
  7. 7.
    Carr JS, Zafar SF, Saba N, Khuri FR, El-Rayes BF. Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer. 2013;44:143–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee YY, Derakhshan MH. Environmental and lifestyle risk factors of gastric cancer. Arch Iran Med. 2013;16:358–65.PubMedGoogle Scholar
  9. 9.
    Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ghahhari NM, Babashah S. Interplay between microRNAs and wnt/beta-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015;51:1638–49.CrossRefPubMedGoogle Scholar
  12. 12.
    Xiong H, Li Q, Liu S, Wang F, Xiong Z, Chen J, et al. Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage i endometrioid endometrial carcinoma. PLoS One. 2014;9, e110163.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chawla JP, Iyer N, Soodan KS, Sharma A, Khurana SK, Priyadarshni P. Role of miRNA in cancer diagnosis, prognosis, therapy and regulation of its expression by epstein-barr virus and human papillomaviruses: with special reference to oral cancer. Oral Oncol. 2015;51:731–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Barger JF, Nana-Sinkam SP. MicroRNA as tools and therapeutics in lung cancer. Respir Med. 2015;109:803–12.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zaravinos A. The regulatory role of microRNAs in emt and cancer. J Oncol. 2015;2015:865816.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, et al. Genomic loss of mir-486 regulates tumor progression and the olfm4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 2011;17:2657–67.CrossRefPubMedGoogle Scholar
  17. 17.
    Tseng CW, Lin CC, Chen CN, Huang HC, Juan HF. Integrative network analysis reveals active microRNAs and their functions in gastric cancer. BMC Syst Biol. 2011;5:99.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wang Y, Feng X, Jia R, Liu G, Zhang M, Fan D, et al. Microarray expression profile analysis of long non-coding RNAs of advanced stage human gastric cardia adenocarcinoma. Mol Genet Genomics. 2014;289:291–302.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen Z, Ma T, Huang C, Zhang L, Xu T, Hu T, et al. MicroRNA-148a: a potential therapeutic target for cancer. Gene. 2014;533:456–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Huang F, Tang J, Zhuang X, Zhuang Y, Cheng W, Chen W, et al. Mir-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-b-inhibitor alpha. PLoS One. 2014;9, e87897.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, et al. Triple-negative and luminal a breast tumors: differential expression of mir-18a-5p, mir-17-5p, and mir-20a-5p. Tumour Biol. 2014;35:7733–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Zheng Q, Ye J, Cao J. Translational regulator eif2alpha in tumor. Tumour Biol. 2014;35:6255–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Stolboushkina EA, Garber MB. Eukaryotic type translation initiation factor 2: structure-functional aspects. Biochemistry Biokhimiia. 2011;76:283–94.CrossRefPubMedGoogle Scholar
  24. 24.
    Lu PD, Jousse C, Marciniak SJ, Zhang Y, Novoa I, Scheuner D, et al. Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. EMBO J. 2004;23:169–79.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47.CrossRefPubMedGoogle Scholar
  26. 26.
    Aktas BH, Qiao Y, Ozdelen E, Schubert R, Sevinc S, Harbinski F, et al. Small-molecule targeting of translation initiation for cancer therapy. Oncotarget. 2013;4:1606–17.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–44.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231–41.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Royce ME, Osman D. Everolimus in the treatment of metastatic breast cancer. Breast Cancer. 2015;9:73–9.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Tan X, Liu Y, Hou J, Cao G. Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus. Onco Targets Therapy. 2015;8:313–21.Google Scholar
  33. 33.
    Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, et al. Mirna-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res. 2010;16:4289–97.CrossRefPubMedGoogle Scholar
  34. 34.
    Lu YC, Chang JT, Liao CT, Kang CJ, Huang SF, Chen IH, et al. Oncomir-196 promotes an invasive phenotype in oral cancer through the nme4-jnk-timp1-mmp signaling pathway. Mol Cancer. 2014;13:218.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Candini O, Spano C, Murgia A, Grisendi G, Veronesi E, Piccinno MS, et al. Mesenchymal progenitors aging highlights a mir-196 switch targeting hoxb7 as master regulator of proliferation and osteogenesis. Stem Cells. 2015;33:939–50.CrossRefPubMedGoogle Scholar
  36. 36.
    Yang G, Han D, Chen X, Zhang D, Wang L, Shi C, et al. Mir-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of IkappaBalpha both in vitro and in vivo. Neuro-Oncology. 2014;16:652–61.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012;167:847–55.CrossRefPubMedGoogle Scholar
  38. 38.
    Pena-Chilet M, Martinez MT, Perez-Fidalgo JA, Peiro-Chova L, Oltra SS, Tormo E, et al. MicroRNA profile in very young women with breast cancer. BMC Cancer. 2014;14:529.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Wang B, Li J, Sun M, Sun L, Zhang X. MiRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. IUBMB life. 2014;66:371–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Rossi M, Kilpinen H, Muona M, Surakka I, Ingle C, Lahtinen J, et al. Allele-specific regulation of disc1 expression by mir-135b-5p. Eur J Hum Genet. 2014;22:840–3.CrossRefPubMedGoogle Scholar
  41. 41.
    Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–5.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Shegan Gao
    • 1
  • Fuyou Zhou
    • 2
  • Chen Zhao
    • 3
  • Zhikun Ma
    • 1
  • Ruinuo Jia
    • 1
  • Shuo Liang
    • 1
  • Mengxi Zhang
    • 1
  • Xiaojuan Zhu
    • 1
  • Pengfei Zhang
    • 1
  • Lu Wang
    • 4
  • Feng Su
    • 4
  • Jiangman Zhao
    • 4
  • Gang Liu
    • 1
  • Bo Peng
    • 4
  • Xiaoshan Feng
    • 1
    • 5
  1. 1.Henan Key Laboratory of Cancer Epigenetic; Cancer InstituteThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China, 471003LuoyangChina
  2. 2.Department of OncologyAnyang People’s HospitalAnyangChina
  3. 3.Fudan-Zhangjiang Center for Clinical GenomicsShanghaiChina
  4. 4.Zhangjiang Center for Translational MedicineShanghaiChina
  5. 5.Henan University of Science and TechnologyLuoyangChina

Personalised recommendations